Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash & Equivalents: 2022-2024

Historic Cash & Equivalents for Immunocore Holdings (IMCR) over the last 3 years, with Dec 2024 value amounting to $455.7 million.

  • Immunocore Holdings' Cash & Equivalents fell 7.32% to $498.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $498.4 million, marking a year-over-year decrease of 7.32%. This contributed to the annual value of $455.7 million for FY2024, which is 2.96% up from last year.
  • Per Immunocore Holdings' latest filing, its Cash & Equivalents stood at $455.7 million for FY2024, which was up 2.96% from $442.6 million recorded in FY2023.
  • Immunocore Holdings' 5-year Cash & Equivalents high stood at $455.7 million for FY2024, and its period low was $402.5 million during FY2022.
  • In the last 3 years, Immunocore Holdings' Cash & Equivalents had a median value of $442.6 million in 2023 and averaged $433.6 million.
  • Data for Immunocore Holdings' Cash & Equivalents shows a peak YoY increased of 9.98% (in 2023) over the last 5 years.
  • Over the past 3 years, Immunocore Holdings' Cash & Equivalents (Yearly) stood at $402.5 million in 2022, then grew by 9.98% to $442.6 million in 2023, then increased by 2.96% to $455.7 million in 2024.